ORION OYJ-CLASS B/ FI0009014377 /
| 15/11/2024 17:24:55 | Chg. -0.75 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 44.54EUR | -1.66% | 11,203 Turnover: 497,501.01 |
-Bid Size: - | -Ask Size: - | 4.77 bill.EUR | 3.63% | 28.96 |
GlobeNewswire
17/07
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation...
GlobeNewswire
01/07
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive ...
GlobeNewswire
03/06
Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire
08/01
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...
GlobeNewswire
05/01
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...
GlobeNewswire
27/12/2023
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
GlobeNewswire
24/03/2022
Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
GlobeNewswire
18/02/2022
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
GlobeNewswire
17/02/2022
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...
GlobeNewswire
03/12/2021
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...
GlobeNewswire
09/06/2021
Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...
GlobeNewswire
09/12/2019
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
GlobeNewswire
31/07/2019
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...
GlobeNewswire
31/05/2019
2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
